Obesity is very common in patients with heart failure with preserved ejection fraction
(HFpEF) and it has been suggested that obesity plays an important role in the …

In recent decades, the epicardial adipose tissue (EAT) has been at the forefront of scientific
research because of its diverse role in the pathogenesis of cardiovascular diseases (CVDs) …

Aims Degenerative aortic valve stenosis with preserved ejection fraction (ASpEF) and heart
failure with preserved ejection fraction (HFpEF) display intriguing similarities. This study …

Background Epicardial adipose tissue (EAT) accumulation is associated with multiple
cardiometabolic risk factors and prognosis of heart failure with preserved ejection fraction …

Heart failure with preserved ejection fraction (HFpEF) has a high prevalence, affecting more
than 50% of patients with heart failure. HFpEF is associated with multiple comorbidities, and …

Owing to the overwhelming obesity epidemic, preserved ejection fraction heart failure
commonly ensues in patients with severe obesity and the obese phenotype of preserved …

Epicardial adipose tissue (EAT) is an endocrine and paracrine organ constituted by a layer
of adipose tissue directly located between the myocardium and visceral pericardium. Under …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are glucose-lowering
agents used for the treatment of type 2 diabetes mellitus, which also improve heart failure …

The prevalence of HF with preserved ejection raction (HFpEF, with EF≥ 50%) is increasing
across all populations with high rates of hospitalization and mortality, reaching up to 80 …

Abstract Purpose of Review An evidence for lipid lowering therapy in heart failure is briefly
summarized in this review. Recent Findings Heart failure therapy is based on recent …